It has been noted that immunotherapy, particularly anti-CTLA4 immunotherapy and 12 antigastric adenocarcinoma drugs, has resulted in a higher survival rate for patients with gastric adenocarcinoma. Here, CTLA4 is linked to adenocarcinoma.